Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma:

a day ago

Study compares anti-PD-1 antibody plus P-GEMOX chemotherapy versus P-GEMOX alone or with autologous stem-cell transplantation (ASCT) for untreated advanced natural killer/T-cell lymphoma (NKTCL).
Immunochemotherapy group (anti-PD-1 + P-GEMOX) showed higher objective response rate (89.6% vs. 77.0%), complete response rate (77.0% vs. 50.5%), and better 3-year progression-free survival (64.1% vs. 40.7%) and overall survival (79.5% vs. 60.8%) compared to chemotherapy group.
Grade 3-4 neutropenia was more common in the immunochemotherapy group (40.0% vs. 20.8%).
Anti-PD-1 maintenance was well tolerated with rare grade ≥3 non-hematologic adverse events.
In propensity score-matched analysis, immunochemotherapy plus anti-PD-1 maintenance had better 3-year disease-free survival (72.6% vs. 50.9%) and overall survival (91.5% vs. 72.9%) compared to chemotherapy plus ASCT.
First-line anti-PD-1 antibody plus P-GEMOX followed by anti-PD-1 maintenance offers superior response and survival outcomes with acceptable toxicity.

Hasty Briefsbeta